Historical position

Renaissance Technologies LLC’s Eli Lilly (LLY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Renaissance Technologies LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2013Earliest verified positive filing snapshot
Latest statusHistorical positionBased on the latest supported relationship state
Peak shares8.29MHighest verified quarter-end share count
Quarters reported45Verified quarters with shares above zero
What happened?

Renaissance Technologies LLC first reported Eli Lilly in Q3 2013. The reported position was increased and reduced across later filings. Verified positive position history runs through Q1 2026. The current relationship status cannot be determined reliably from supported data.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q1 2026
Sold 56.7% of the position−94.06K shares · 71.79K shares remained
Filing context

Quarter-end price $919.77

Q4 2025
New position+165.85K shares · 165.85K shares reported
Filing context

Quarter-end price $1,074.68

Q2 2025
Sold 99.7% of the position−96.05K shares · 261 shares remained
Filing context

Quarter-end price $784.15

Q1 2025
Bought 78.0% more+42.19K shares · 96.31K shares reported after the change
Filing context

Quarter-end price $825.92

Q4 2024
Sold 79.0% of the position−203.69K shares · 54.12K shares remained
Filing context

Quarter-end price $772.02

Q3 2024
New position+257.81K shares · 257.81K shares reported
Filing context

Quarter-end price $885.94

Portfolio importance

How important was Eli Lilly in Renaissance Technologies LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.1%Q1 2026
Last reported rank#245Rank unavailable
Peak portfolio weight1.0%Q3 2013
Best historical rank#7Q3 2013
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$1,164.892026-09-21

Market context only; not an investor transaction price.

Latest filing quarter-end price$919.77Q1 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

View Eli Lilly stock page →

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Renaissance’s secret models, complete trading book, exact trade dates or execution prices.